The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .
Every adult (age ≥ 18 years) seen in one of the 3 participating centre (dijon, Marseille, Mondor) over a 7-year period (2005-2012) with a definite diagnosis of primary ITP according to the American Society Hematology guidelines who received RTX regardless the regimen could be included.
Study Type
OBSERVATIONAL
Enrollment
107
The primary end point of the study was to assess the response rate to treatment 1 year after the first rituximab infusion.
A complete response (CR) was defined as a platelet count \>100 x 109/l and a response (R): by a platelet count \>30 x 109/l with a least a doubling of the baseline value without any rescue intervention within 8 weeks before assessment, and no response (NR) was defined as a platelet count lower than 30 x 109/
Time frame: one year
The response rate 3months, and at the last follow-up after the first rituximab infusion. Variable associated with RTX response.
Time frame: 3 months, one year, last follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.